The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials

Errata

This article corrects:

  1. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials Volume 41, Issue 9, 1282–1288, Article first published online: 7 March 2011

J.-M. Grouin, E. Vicaut, S. Jean-Alphonse, P. Demoly, U. Wahn, A. Didier, O. de Beaumont, A. Montagut, M. Le Gall and P. Devillier. Clin Exp Allergy 2011; 41: 1282–8.

On p. 1283, column 1, 4th paragraph, line 5 should read:

“In response to the EMA's request for the establishment of a balanced, validated scoring system [4], the average AdSS was recently accepted as primary end-point in allergen immunotherapy”, rather than “The EMA has recently accepted use of the average AdSS as a primary end-point in allergen immunotherapy trials [4]”.

Similarly, on p. 1287, column 2, 2nd paragraph, line 3 should read:

“In response to the EMA's request for the establishment of a balanced, validated scoring system [4], the average AdSS was recently accepted for use as a primary end-point in rhinoconjunctivitis allergen immunotherapy trials”, rather than “In response to the EMA's request for the establishment of a balanced, validated scoring system, the average AdSS was recently accepted for use as a primary end-point in rhinoconjunctivitis allergen immunotherapy trials [4]”.

Reference [4] was cited at the wrong position in the sentences in question and may have given the impression that the EMA Guideline itself specifically approved the AdSS. We apologize for any confusion that this may have caused.

Ancillary